Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Abbv crawled time : 13:00 save search
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
qulipta abbvie treatment for migraine
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
Published: 2024-03-06 (Crawled : 13:00) - prnewswire.com
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: 0.09%
H: 2.11%
C: 1.49%
abbvie meeting
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
Published: 2024-02-22 (Crawled : 13:00) - prnewswire.com
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: -0.88%
H: 1.46%
C: 1.13%
abbvie collaboration immunology
BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs
Published: 2024-02-21 (Crawled : 13:00) - prnewswire.com
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: -0.25%
H: 0.0%
C: 0.0%
botox women grant program
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
Published: 2024-02-15 (Crawled : 13:00) - biospace.com/
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: 0.48%
H: 1.56%
C: 1.48%
IRWD | $7.65 130K
|
Health Technology
|
| O: -5.63%
H: 7.34%
C: 2.81%
year pharmaceuticals ironwood financial
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
Published: 2024-01-08 (Crawled : 13:00) - prnewswire.com
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
positive program trial results
AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call
Published: 2024-01-04 (Crawled : 13:00) - prnewswire.com
GNMSF | $281.02 210
|
Health Technology
|
| O: 0.16%
H: 1.95%
C: 1.94%
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
GMAB | $28.29 -0.84% 31K
|
Health Technology
|
| O: 1.25%
H: 0.99%
C: 0.63%
conference abbvie
AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 13:00) - prnewswire.com
GNMSF | $281.02 210
|
Health Technology
|
| O: -0.78%
H: 4.49%
C: 1.55%
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: -0.09%
H: 3.38%
C: 3.18%
GMAB | $28.29 -0.84% 31K
|
Health Technology
|
| O: -1.54%
H: 3.6%
C: 2.42%
CERE 4 | $41.82 0.53% 170K
|
Finance
|
| O: -0.14%
H: 0.19%
C: -0.31%
conference abbvie
Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
Published: 2023-10-24 (Crawled : 13:00) - biospace.com/
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
positive treatment topline results
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
abbvie dermatitis rinvoq
AbbVie to Host Third-Quarter 2023 Earnings Conference Call
Published: 2023-10-04 (Crawled : 13:00) - biospace.com/
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
conference abbvie
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
Published: 2023-08-08 (Crawled : 13:00) - biospace.com/
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
IRWD | $7.65 130K
|
Health Technology
|
| O: -3.96%
H: 0.0%
C: -5.41%
linzess sales year pharmaceuticals ironwood
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023
Published: 2023-05-11 (Crawled : 13:00) - biospace.com/
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: 0.59%
H: 0.19%
C: -0.48%
SMMT A | $3.55 -0.56% 63K
|
Health Technology
|
| O: 0.47%
H: 0.47%
C: -9.62%
therapeutics financial results
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
Published: 2023-04-26 (Crawled : 13:00) - biospace.com/
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: -1.35%
H: 0.36%
C: -0.54%
XNCR | $18.94 -0.68% 23K
|
Health Technology
|
| O: -0.5%
H: 0.82%
C: -3.72%
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million
Published: 2023-04-25 (Crawled : 13:00) - biospace.com/
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: 0.44%
H: 0.84%
C: 0.05%
ENTA | News | $13.51 -3.5% 19K
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: -5.7%
mavyret life royalties pharmaceuticals sciences global
Hyaluronic acid market size to grow by USD 3,719.76 million between 2022 and 2027, Growth driven by the huge requirement for safe and stable drugs that require minimal monitoring - Technavio
Published: 2023-04-11 (Crawled : 13:00) - prnewswire.com
SNYNF | News | $92.7 0.63% 0
|
Health Technology
|
| O: -1.75%
H: 0.0%
C: 0.0%
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: 0.13%
H: 0.68%
C: -0.07%
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
ANIK | $25.655 -0.14% 5.2K
|
Health Technology
|
| O: -3.52%
H: 4.28%
C: 1.38%
growth market
AbbVie Clinches Back-to-Back Clinical Wins in Ulcerative Colitis, Lupus
Published: 2023-03-24 (Crawled : 13:00) - biospace.com/
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: -0.01%
H: 2.06%
C: 1.76%
abbvie lupus ulcerative colitis
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
Published: 2023-03-22 (Crawled : 13:00) - prnewswire.com
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: -0.7%
H: 0.77%
C: -1.29%
abbv-951 drug abbvie update application
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
Published: 2023-02-09 (Crawled : 13:00) - biospace.com/
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: 2.69%
H: 3.5%
C: 0.13%
abbvie financial results
Emergency contraceptive pills market to grow by 3.72% Y-O-Y from 2022 to 2023: Rise in the number of initiatives to create awareness will drive growth -Technavio
Published: 2023-01-30 (Crawled : 13:00) - prnewswire.com
ABBV | $166.49 1.36% 720K
|
Health Technology
|
| O: -0.28%
H: 0.86%
C: -0.15%
contraceptive growth market
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
TIRX | $1.13 133.09% 44M
|
AGBA | $0.8978 124.45% 60M
|
Finance
BPTH | $6.18 90.74% 39M
|
Health Technology
INVO | $1.44 89.47% 3M
|
Health Technology
XPON | $2.66 37.82% 5.2M
|
SINT | $0.0504 35.12% 300M
|
Health Technology
THCH | $1.38 32.69% 9.9M
|
n/a
ALRN | $5.605 31.88% 210K
|
Health Technology
HOLO | $2.92 30.36% 22M
|
VTNR S | $1.25 27.66% 3.2M
|
Industrial Services
Your saved searches
Save your searches and get alerts when important news are released.